Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.31
Bid: 1.30
Ask: 1.33
Change: 0.00 (0.00%)
Spread: 0.03 (2.308%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.31
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

12 Jun 2020 07:00

RNS Number : 7354P
RTW Venture Fund Limited
12 June 2020
 

LEI: 549300Q7EXQQH6KF7Z84

12 June 2020

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 May 2020 (the "NAV") was US$217.8 million, or US$1.22 per ordinary share.

As at 31 May 2020, 12.2 per cent. of the total NAV was invested in privately-held companies.

For Further Information

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Ocorian (Company Secretary) +44 (0)1481 742 642Kevin Smith

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

Alwyn Clarke

Ryan McCarthy

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 May 2020. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVGPUBCQUPUGQG
Date   Source Headline
20th May 20218:05 amRNSNew Investment in Numab Therapeutics
14th May 20217:00 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSAnnual Financial Report
28th Apr 20217:00 amRNSQuarterly Update
19th Apr 20217:00 amRNSPortfolio Company Update: Biomea IPO
15th Apr 20217:00 amRNSNet Asset Value(s)
1st Apr 20217:05 amRNSTotal Voting Rights
1st Apr 20217:00 amRNSNotice of Annual Report
30th Mar 20211:00 pmRNSNew Investment in Pyxis Oncology
17th Mar 20217:00 amRNSIssue of Equity
15th Mar 20217:01 amRNSAnnouncement of Share Issuance
15th Mar 20217:00 amRNSPortfolio Company Update: Prometheus IPO
12th Mar 202112:30 pmRNSNew Investment in Monte Rosa Therapeutics
12th Mar 20217:00 amRNSNet Asset Value(s)
9th Mar 20211:45 pmRNSNew Investment in Ventyx Biosciences
9th Mar 202112:45 pmRNSNew Investment in Visus Therapeutics
1st Mar 20211:00 pmRNSNew Investment in Tenaya Therapeutics
1st Mar 20217:00 amRNSTotal Voting Rights
26th Feb 20211:15 pmRNSNew Investment in Artiva Biotherapeutics
18th Feb 20217:00 amRNSIssue of Equity
15th Feb 20214:10 pmRNSAnnouncement of Share Issuance
15th Feb 20217:00 amRNSNet Asset Value(s)
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance
13th Nov 20207:00 amRNSNet Asset Value(s)
10th Nov 20209:26 amRNSHolding(s) in Company
9th Nov 20202:00 pmRNSNew Investment in Prometheus Biosciences
2nd Nov 20207:00 amRNSTotal Voting Rights
28th Oct 20201:25 pmRNSHolding(s) in Company
19th Oct 20207:01 amRNSTarsus Pharmaceuticals Prices $88 Million IPO
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.